Nature Communications (Jan 2023)
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
- L. Paige Ferguson,
- Jovylyn Gatchalian,
- Matthew L. McDermott,
- Mari Nakamura,
- Kendall Chambers,
- Nirakar Rajbhandari,
- Nikki K. Lytle,
- Sara Brin Rosenthal,
- Michael Hamilton,
- Sonia Albini,
- Martin Wartenberg,
- Inti Zlobec,
- José A. Galván,
- Eva Karamitopoulou,
- Vera Vavinskaya,
- Alexis Wascher,
- Andrew M. Lowy,
- Christian M. Schürch,
- Pier Lorenzo Puri,
- Benoit G. Bruneau,
- Diana C. Hargreaves,
- Tannishtha Reya
Affiliations
- L. Paige Ferguson
- Department of Pharmacology, University of California San Diego School of Medicine
- Jovylyn Gatchalian
- Salk Institute for Biological Studies
- Matthew L. McDermott
- Department of Pharmacology, University of California San Diego School of Medicine
- Mari Nakamura
- Department of Pharmacology, University of California San Diego School of Medicine
- Kendall Chambers
- Department of Pharmacology, University of California San Diego School of Medicine
- Nirakar Rajbhandari
- Department of Pharmacology, University of California San Diego School of Medicine
- Nikki K. Lytle
- Salk Institute for Biological Studies
- Sara Brin Rosenthal
- Center for Computational Biology and Bioinformatics, University of California San Diego School of Medicine
- Michael Hamilton
- Department of Pharmacology, University of California San Diego School of Medicine
- Sonia Albini
- Genethon
- Martin Wartenberg
- Institute of Pathology, University of Bern
- Inti Zlobec
- Institute of Pathology, University of Bern
- José A. Galván
- Institute of Pathology, University of Bern
- Eva Karamitopoulou
- Institute of Pathology, University of Bern
- Vera Vavinskaya
- Department of Pathology, University of California San Diego School of Medicine
- Alexis Wascher
- Moores Cancer Center, University of California San Diego School of Medicine
- Andrew M. Lowy
- Moores Cancer Center, University of California San Diego School of Medicine
- Christian M. Schürch
- Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen
- Pier Lorenzo Puri
- Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute
- Benoit G. Bruneau
- Gladstone Institutes, Roddenberry Center for Stem Cell Biology and Medicine
- Diana C. Hargreaves
- Salk Institute for Biological Studies
- Tannishtha Reya
- Department of Pharmacology, University of California San Diego School of Medicine
- DOI
- https://doi.org/10.1038/s41467-023-35796-7
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 17
Abstract
Clinical management of pancreatic cancer remains challenging. Here, the authors suggest SMARCD3 as a potential epigenetic dependency establishing the metabolic landscape in aggressive pancreatic cancer cells and as a potential therapeutic target in pancreatic cancer.
